Sepracor has reported positive Phase III combined clinical results for eslicarbazepine acetate in the treatment of epilepsy.

Aradigm has started a multicenter Phase II clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.

Cardo Medical and clickNsettle.com have signed a merger agreement pursuant to which Cardo Medical will become a wholly owned subsidiary of clickNsettle.

Forest Laboratories has announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus and gram negative bacteria, for the treatment of complicated skin and

Spectrum Pharmaceuticals has announced the formation of a Canadian affiliate, Spectrum Pharma Canada, headquartered in the province of Quebec, Canada.

Metabasis Therapeutics has announced the results of its 14-day, Phase Ib multiple-dose clinical trial in subjects with mild hypercholesterolemia, which showed that MB07811 was safe and well tolerated across the seven doses tested, ranging from 0.25mg up to 40mg.

DocuSys, a provider of anesthesia information management solutions, has relocated its headquarters to Atlanta.

Allarae HealthCare and Lobeck Medical have announced a long term joint venture agreement and product distribution alliance.

InSight Health Services Holdings has announced that a wholly owned subsidiary of the company has completed the sale of its final diagnostic imaging center located in the San Fernando Valley of Southern California to RadNet Management.

Perrigo Company has received final approval from the FDA to manufacture and market Cetirizine hydrochloride syrup, 1mg/ml.

Avanir Pharmaceuticals has announced that the European Patent Office has granted the company a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia into 2023.

Agendia has opened its new headquarters at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406, Netherlands. The company has also expanded its laboratory facilities at the new location.

Shenzhen Beike Biotechnology has started outfitting its 21,500 square foot comprehensive medical stem cell storage and processing facility in eastern China.

ThermoGenesis has announced that TUV has issued an EC certificate for the MarrowXpress system, which allows the company to affix the CE mark and commence selling the product in the European community.

PPD has opened a new office in Istanbul, Turkey, continuing the growth of its Phase II-IV clinical development services in Eastern Europe. PPD will provide clinical monitoring services in key therapeutic areas from this location.

Osi Pharmaceuticals has initiated the first-in-human clinical study of its development compound PSN602, an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity.

US based biotechnology company Lux Biosciences has appointed Brett Skolnik as its new CFO.

Cigna HealthCare of Florida has renewed its contract with Mercy Hospital for two years.

Merck KGaA has submitted an application to the European Medicines Agency to broaden the use of the targeted therapy Erbitux to include first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

ArthroCare has launched its new DoublePlay implant, a novel suture anchor device intended for soft tissue to bone fixation in surgical procedures such as rotator cuff repair.